{"id":192831,"date":"2026-07-12T02:44:57","date_gmt":"2026-07-12T08:14:57","guid":{"rendered":"https:\/\/newslink360.space\/?p=192831"},"modified":"2026-07-12T02:44:57","modified_gmt":"2026-07-12T08:14:57","slug":"staging-preclinical-alzheimers-disease-pathologies","status":"publish","type":"post","link":"https:\/\/newslink360.space\/?p=192831","title":{"rendered":"Staging Preclinical Alzheimer&#8217;s Disease Pathologies"},"content":{"rendered":"<p><br \/>\n<\/p>\n<div>\n<p id=\"p-rc_17cddad731271b5e-40\" data-path-to-node=\"11\"><span data-path-to-node=\"11,0\">COMBINED tau biomarkers track early cognitive decline and forecast structural neurodegeneration in <a href=\"https:\/\/www.emjreviews.com\/en-us\/amj\/neurology\/news\/alzheimers-disease-diagnosis-enters-a-new-era\/\" target=\"_blank\" rel=\"noopener\">preclinical Alzheimer\u2019s<\/a> disease<\/span><span data-path-to-node=\"11,2\">. Clinicians evaluating asymptomatic individuals with confirmed amyloid-beta deposition frequently face significant prognostic challenges due to variable disease trajectories<\/span><span data-path-to-node=\"11,4\">. While plasma biomarkers offer high diagnostic sensitivity, they lack spatial precision regarding fibrillar protein localization in specific neural tissues<\/span><span data-path-to-node=\"11,6\">. To address these practical limitations, a prospective multicenter clinical trial evaluated 330 cognitively unimpaired adults over an extended five-year tracking period to determine if integrating blood fluid assays with standard neuroimaging optimizes patient staging<\/span><span data-path-to-node=\"11,8\">. All participants were confirmed to be amyloid-positive at baseline using florbetapir imaging to capture the early pathological changes<\/span><span data-path-to-node=\"11,10\">.<\/span><\/p>\n<h2 data-path-to-node=\"12\">Trajectories Across Preclinical Alzheimer\u2019s Disease<\/h2>\n<p id=\"p-rc_17cddad731271b5e-41\" data-path-to-node=\"13\"><span data-path-to-node=\"13,0\">The investigators stratified the asymptomatic sample using baseline plasma phosphorylated tau-217 levels along with standardized visual evaluations of approved flortaucipir positron emission tomography scans<\/span><span data-path-to-node=\"13,2\">. Patients presenting with concordant positivity across both diagnostic modalities represented the highest-risk category within the classic neurodegenerative cascade<\/span><span data-path-to-node=\"13,4\">. This positive-concordant subpopulation exhibited extensive baseline cortical amyloid burden, accelerated fronto-temporo-parietal tau protein dissemination, and severe gray matter volume loss over follow-up<\/span><span data-path-to-node=\"13,6\">. Conversely, individuals demonstrating discordant biomarker profiles, such as elevated blood markers paired with negative visual scans, experienced much slower biological progression, suggesting either low-tau states or an early transitional phase<\/span><span data-path-to-node=\"13,8\">.<\/span><\/p>\n<h2 data-path-to-node=\"14\">Clinical Implications for Healthcare Providers<\/h2>\n<p id=\"p-rc_17cddad731271b5e-42\" data-path-to-node=\"15\"><span data-path-to-node=\"15,0\">Longitudinal cognitive assessments using structured composite scoring tools confirmed that dual-biomarker concordance strongly correlates with severe cognitive decline over time<\/span><span data-path-to-node=\"15,2\">. Path mediation analysis demonstrated that approximately 52% of the relationship between progressive tau aggregation and memory impairment is directly driven by structural cortical atrophy<\/span><span data-path-to-node=\"15,4\">. For medical specialists, nuclear medicine physicians, and primary care providers, these findings indicate that binary classification is no longer sufficient for managing preclinical Alzheimer\u2019s disease cases<\/span><span data-path-to-node=\"15,6\">. Implementing a dual-biomarker strategy allows physicians to refine early risk prediction, identify optimal candidates for prevention trials, and strategically implement disease-modifying therapies prior to clinical symptom onset<\/span><span data-path-to-node=\"15,8\">.<\/span><\/p>\n<p data-path-to-node=\"17\"><strong>Reference<\/strong><\/p>\n<p data-path-to-node=\"17\">Labrador-Espinosa MA et al. Clinico-biological trajectories stratified by combined tau biomarkers in preclinical Alzheimer\u2019s disease. Alzheimer\u2019s Research &amp; Therapy. 2026;18:154.<\/p>\n<p data-path-to-node=\"18\"><em>Featured Image: Framestock on Adobe Stock.<\/em><\/p>\n<\/div>\n<p><br \/>\n<br \/><a href=\"https:\/\/www.emjreviews.com\/neurology\/news\/new-biomarker-approach-maps-preclinical-alzheimers-disease-risk\/\" target=\"_blank\" rel=\"noopener\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>COMBINED tau biomarkers track early cognitive decline and forecast structural neurodegeneration in preclinical Alzheimer\u2019s disease. Clinicians evaluating asymptomatic individuals with confirmed amyloid-beta deposition frequently face significant prognostic challenges due to variable disease trajectories. While plasma biomarkers offer high diagnostic sensitivity, they lack spatial precision regarding fibrillar protein localization in specific neural tissues. To address these &#8230; <a title=\"Staging Preclinical Alzheimer&#8217;s Disease Pathologies\" class=\"read-more\" href=\"https:\/\/newslink360.space\/?p=192831\" aria-label=\"Read more about Staging Preclinical Alzheimer&#8217;s Disease Pathologies\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":192832,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7],"tags":[],"class_list":["post-192831","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-national-news"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/newslink360.space\/wp-content\/uploads\/2026\/07\/AdobeStock_732056927.jpeg","jetpack_likes_enabled":true,"jetpack-related-posts":[{"id":189753,"url":"https:\/\/newslink360.space\/?p=189753","url_meta":{"origin":192831,"position":0},"title":"Inflammation Signatures Linked to AD Decline","author":"Ajay Kumar Verma","date":"July 4, 2026","format":false,"excerpt":"POORER cognition linked to altered blood-based inflammatory signatures and neurodegeneration\u00a0in Alzheimer\u2019s disease (AD) according to new research investigating immune profiles across a diverse patient cohort. The findings suggest that plasma cytokine patterns could help\u00a0identify\u00a0biological subgroups of patients and support more targeted approaches to immunomodulatory therapies.\u00a0\u00a0 Study Identifies Distinct Inflammatory Signatures\u2026","rel":"","context":"In &quot;National News&quot;","block_context":{"text":"National News","link":"https:\/\/newslink360.space\/?cat=7"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/12pm-Neuro.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/12pm-Neuro.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/12pm-Neuro.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/12pm-Neuro.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":187624,"url":"https:\/\/newslink360.space\/?p=187624","url_meta":{"origin":192831,"position":1},"title":"Alzheimer Disease Blood Biomarkers After TBI","author":"Ajay Kumar Verma","date":"June 29, 2026","format":false,"excerpt":"ALZHEIMER disease blood biomarkers may be less accurate in veterans with prior traumatic brain injury. Alzheimer Disease Blood Biomarkers Show Reduced Accuracy A history of traumatic brain injury (TBI) may reduce the diagnostic accuracy of emerging Alzheimer disease blood biomarkers, according to new findings from a cross-sectional diagnostic test study\u2026","rel":"","context":"In &quot;National News&quot;","block_context":{"text":"National News","link":"https:\/\/newslink360.space\/?cat=7"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/06\/AdobeStock_913247615.jpeg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/06\/AdobeStock_913247615.jpeg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/06\/AdobeStock_913247615.jpeg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/06\/AdobeStock_913247615.jpeg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":183478,"url":"https:\/\/newslink360.space\/?p=183478","url_meta":{"origin":192831,"position":2},"title":"AKAP1 Metabolic Pathway Drives Liver Cancer Growth","author":"Ajay Kumar Verma","date":"June 21, 2026","format":false,"excerpt":"KEY driver of liver cancer growth identified in a new study suggests that a mitochondrial protein may play a central role in reprogramming how cells store and utilise glycogen, highlighting a previously underappreciated metabolic pathway in cancer development and offering a potential new therapeutic target for hepatocellular carcinoma (HCC). The\u2026","rel":"","context":"In &quot;National News&quot;","block_context":{"text":"National News","link":"https:\/\/newslink360.space\/?cat=7"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/06\/10am-Hep.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/06\/10am-Hep.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/06\/10am-Hep.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/06\/10am-Hep.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":192821,"url":"https:\/\/newslink360.space\/?p=192821","url_meta":{"origin":192831,"position":3},"title":"Precision Medicine Shows Promise In Advanced Gastric Cancer","author":"Ajay Kumar Verma","date":"July 12, 2026","format":false,"excerpt":"PRECISION medicine is transforming first line treatment for advanced gastric cancer by prioritizing biomarker guided therapy selection and more personalized clinical decision making. Precision Medicine Moves to the Forefront Advanced gastric cancer remains associated with poor survival, particularly because many patients present with unresectable or metastatic disease. The newly published\u2026","rel":"","context":"In &quot;National News&quot;","block_context":{"text":"National News","link":"https:\/\/newslink360.space\/?cat=7"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/AdobeStock_236894546.jpeg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/AdobeStock_236894546.jpeg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/AdobeStock_236894546.jpeg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/AdobeStock_236894546.jpeg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":187804,"url":"https:\/\/newslink360.space\/?p=187804","url_meta":{"origin":192831,"position":4},"title":"Paroxetine Targets Neurovascular-Immune Pathways in Rosacea","author":"Ajay Kumar Verma","date":"June 30, 2026","format":false,"excerpt":"NEW research has explored how paroxetine may improve symptoms of refractory erythematous rosacea by altering systemic molecular pathways. The secondary analysis of a randomised clinical trial investigated changes in plasma proteins after treatment and identified potential biomarkers that could help predict which patients may respond. The study included 24 women\u2026","rel":"","context":"In &quot;National News&quot;","block_context":{"text":"National News","link":"https:\/\/newslink360.space\/?cat=7"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/06\/12pm-derm-1-940x587.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/06\/12pm-derm-1-940x587.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/06\/12pm-derm-1-940x587.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/06\/12pm-derm-1-940x587.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":191049,"url":"https:\/\/newslink360.space\/?p=191049","url_meta":{"origin":192831,"position":5},"title":"Seminal Plasma Biomarkers Predict Sperm Retrieval","author":"Ajay Kumar Verma","date":"July 7, 2026","format":false,"excerpt":"ACCURATE prediction of sperm retrieval outcomes using a simple, non-invasive seminal plasma assay in men with non-obstructive azoospermia (NOA), according to new data presented at the 42nd Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) in London, UK. Men with NOA have severely impaired sperm production,\u2026","rel":"","context":"In &quot;National News&quot;","block_context":{"text":"National News","link":"https:\/\/newslink360.space\/?cat=7"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/ESHRE-Tues.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/ESHRE-Tues.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/ESHRE-Tues.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/newslink360.space\/wp-content\/uploads\/2026\/07\/ESHRE-Tues.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]}],"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/pgnRh4-Oab","_links":{"self":[{"href":"https:\/\/newslink360.space\/index.php?rest_route=\/wp\/v2\/posts\/192831","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/newslink360.space\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/newslink360.space\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/newslink360.space\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/newslink360.space\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=192831"}],"version-history":[{"count":0,"href":"https:\/\/newslink360.space\/index.php?rest_route=\/wp\/v2\/posts\/192831\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/newslink360.space\/index.php?rest_route=\/wp\/v2\/media\/192832"}],"wp:attachment":[{"href":"https:\/\/newslink360.space\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=192831"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/newslink360.space\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=192831"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/newslink360.space\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=192831"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}